Gene · 2217
Papers4,523
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
381 to 400 of 4,523
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Target-Mediated Drug Disposition (TMDD) Revisited: High Versus Low-Affinity Approximations of the TMDD Model. | CPT Pharmacometrics Syst Pharmacol | 2025 | 40423689 | PubTator, text mining | PubMed |
| Fe2+ Triggers Endocytosis of Carrier Proteins in Mammalian Cells. | Adv Healthc Mater | 2025 | 40420645 | PubTator, text mining | PubMed |
| Enhanced plasma half-life and efficacy of engineered human albumin-fused GLP-1 despite enzymatic cleavage of its C-terminal end. | Commun Biol | 2025 | 40419755 | PubTator, text mining | PubMed |
| Finerenone effects on biomarkers: an analysis from the FIGARO-DKD trial. | Eur Heart J | 2025 | 40415577 | PubTator, text mining | PubMed |
| FcRn-silencing of IL-12Fc prevents toxicity of local IL-12 therapy and prolongs survival in experimental glioblastoma. | Nat Commun | 2025 | 40404625 | PubTator, text mining | PubMed |
| Development of a Novel Engineered Antibody Format for PSMA-Targeted Radionuclide Therapy. | Mol Pharm | 2025 | 40403225 | PubTator, text mining | PubMed |
| Real world study in Italian public hospital with Efgartigimod in patients affected by generalized myasthenia gravis: influence of clinical and serological factors. | Front Neurol | 2025 | 40401017 | PubTator, text mining | PubMed |
| Dose Optimization of rhIL-7-hyFc for Patients With Lymphopenia Using a Neonatal Fc Receptor-Mediated Recycling-Based and Target-Mediated Drug Disposition Pharmacokinetic Model. | Clin Transl Sci | 2025 | 40396986 | PubTator, text mining | PubMed |
| Chronic Inflammatory Demyelinating Polyneuropathy: How Pathophysiology Can Guide Treatment. | Muscle Nerve | 2025 | 40391517 | PubTator, text mining | PubMed |
| Progress of arylacetamide deacetylase research in metabolic diseases. | Front Oncol | 2025 | 40376582 | PubTator, text mining | PubMed |
| Short-term treatment of CIDP with efgartigimod: a case series in China. | Front Immunol | 2025 | 40375986 | PubTator, text mining | PubMed |
| The new era of primary immune thrombocytopenia management in adults: A narrative review of current and emerging treatments. | Blood Rev | 2025 | 40374446 | PubTator, text mining | PubMed |
| Engineering of long-acting human growth hormone-Fc fusion proteins: Effects of valency, fusion position, and linker design on pharmacokinetics and efficacy. | PLoS One | 2025 | 40373007 | PubTator, text mining | PubMed |
| Autoimmune bullous diseases: pathogenesis and clinical management. | Mol Biomed | 2025 | 40372624 | PubTator, text mining | PubMed |
| Non-Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol-Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial. | Nephrology (Carlton) | 2025 | 40369895 | PubTator, text mining | PubMed |
| Virtual Screening Combined with Phase Transition-FRET for Discovery of Small-Molecule FcRn Antagonists. | Anal Chem | 2025 | 40369714 | PubTator, text mining | PubMed |
| FDA approves J&J's FcRn blocker for generalized myasthenia gravis. | Nat Rev Drug Discov | 2025 | 40335719 | PubTator, text mining | PubMed |
| Leveraging neonatal Fc receptor (FcRn) to enhance antibody transport across the blood brain barrier. | Nat Commun | 2025 | 40319060 | PubTator, text mining | PubMed |
| Autoimmune neuro-ophthalmic disorders: pathophysiologic mechanisms and targeted biologic therapies. | Expert Opin Biol Ther | 2025 | 40298278 | PubTator, text mining | PubMed |
| A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy. | Front Immunol | 2025 | 40297573 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2217/papers?page=20